

JUN 3, 2024

Company: Chiome Bioscience Inc.

Representative: Shigeru Kobayashi, President & CEO

(Code: 4583, Tokyo Stock Exchange Growth)

**Presentation of Research Results using Chiome's Antibody
at the 67th Annual Meeting of the Japanese Society of Nephrology**

The study results in which Chiome's anti-Semaphorin 3A monoclonal antibody was used will be presented by a research group of the Department of Nephrology, Rheumatology, Endocrinology and Metabolism at the Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, at the 67th Annual Meeting of the Japanese Society of Nephrology, held at Pacifico Yokohama, June 28 (Friday) to June 30 (Sunday), 2024.

In this research, anti-Semaphorin 3A antibody obtained with Chiome's ADLib® system was used. In this presentation, data on disease suppression effect of anti-Semaphorin 3A antibody on renal fibrosis mouse model will be presented.

An overview of the presentation is as follows.

Abstract Number: O-032

Date and Time: Friday, June 28, 2024, 10:00 – 11:00 a.m.

Presentation format: oral presentation

Title: Inhibition of renal fibrosis by anti-Semaphorin 3A antibody

[The 67th Annual Meeting of the Japanese Society of Nephrology\(umin.jp\)](https://www.umin.jp/)

<ADLib® system>

It is a technology to generate antibodies by recombinant activation of antibody genes in chicken DT40 cells and has following characteristics: 1) Rapid production of therapeutic and diagnostic candidate antibodies (as little as 10 days from selection to screening), 2) Capable of generating antibodies based on a unique diversification mechanism and 3) Easy to enhance the binding strength of the obtained antibody to its target (affinity maturation). ADLib® is our registered trademark.

<Anti-Semaphorin 3A Antibody>

Semaphorin 3A has been found as a factor that controls nerve tip elongation. Research to date has shown that nerve regeneration occurs by inhibiting Semaphorin 3A. It has also been reported to be related with inflammation, immunoreaction, cancer, bone formation, Alzheimer's disease, diabetes complication, and other diseases. Our company has acquired anti-Semaphorin 3A through collaboration with Professor Yoshio Goshima of Yokohama City University as an antibody that combines selectivity and function inhibitory activity. We are currently working on out-licensing activities under the project code BMAA.

【Inquiries】

Chiome Bioscience Inc. Investor Relations

E-mail: ir@chiome.co.jp